First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease

Author: Benzinga Newsdesk | May 16, 2024 06:30am

 Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (NASDAQ:ENTO) ("Entero" or the "Company"), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today unveiled its new corporate name and website. The rebranding follows the recent business combination with ImmunogenX and reflect the Company's focus on addressing unmet needs in GI health that include celiac disease, an indication for which there are no approved medicines today. Entero's common stock will commence trading on May 17, 2024, on the Nasdaq Capital Market under the new ticker symbol of ENTO.

Posted In: ENTO FWBI